MRK-016
MRK-016 is an anxiolytic drug which is a novel type of GABA-A receptor positive allosteric modulator. It was developed by Merck & Co and has been researched for potential medical use but never marketed.
Pharmacology[edit | edit source]
MRK-016 is a subtype-selective GABA-A receptor positive allosteric modulator. Unlike most GABA-A modulators, which usually produce strong sedation and ataxia in addition to anxiolytic effects, MRK-016 is anxiolytic but with little or no sedative effects, because it is selective for the α2 and α3 subtypes of the GABA-A receptor, which are responsible for the anxiolytic effects of these drugs, but does not affect the α1 subtype, which produces the sedative and ataxic effects.
Development[edit | edit source]
MRK-016 was developed by Merck & Co as part of their research program into subtype-selective GABA-A modulators. It has been researched in animal studies and shown to produce anxiolytic effects without sedation, but has not been developed for medical use and is not currently marketed.
See also[edit | edit source]
MRK-016 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD